Plagiarism/Ethics Statement
Plagiarism and Publication Ethics Statement
Annals of Leukemia Research is committed to maintaining the highest standards of publication ethics, scientific integrity, and responsible research practices. The journal serves as a platform for the dissemination of high-quality research in leukemia, hematologic malignancies, stem cell biology, molecular oncology, clinical hematology, precision medicine, and related biomedical disciplines. Authors, reviewers, editors, and editorial staff are expected to uphold ethical principles that ensure the credibility and reliability of the scientific record.
Authors must submit manuscripts that are original, scientifically accurate, and not under consideration by another journal. All published and unpublished sources, including text, data, figures, tables, and ideas, must be properly acknowledged through appropriate citation and referencing. The journal has zero tolerance for plagiarism, self-plagiarism, duplicate publication, data fabrication, data falsification, image manipulation, or any other form of research misconduct. Manuscripts suspected of violating ethical standards may be rejected during peer review or, if published, may be corrected, retracted, or otherwise addressed following a thorough editorial investigation.
Research involving human participants must be conducted in accordance with internationally recognized ethical principles and applicable institutional and national regulations. Where required, authors should obtain approval from an appropriate Institutional Review Board (IRB) or Ethics Committee before initiating the study and confirm that informed consent was obtained from all participants or their legally authorized representatives. Patient confidentiality and privacy must be protected, and personally identifiable information should only be published with explicit written consent.
Studies involving animals must comply with recognized ethical standards for the care and use of laboratory animals. Authors should provide details of the relevant ethical approvals and describe the measures taken to ensure humane treatment throughout the research process.
The journal requires complete disclosure of all sources of funding, financial support, and any actual or potential conflicts of interest that could influence the design, conduct, analysis, or interpretation of the research. Individual author contributions should be clearly described to promote accountability and transparency. Authors are encouraged to retain original research data and, where appropriate, make supporting data available to facilitate validation and reproducibility.
Editors are responsible for ensuring an impartial, confidential, and timely editorial process. Manuscripts are evaluated solely on the basis of scientific merit, originality, methodological quality, ethical compliance, and relevance to the journal's scope. Reviewers are expected to provide objective, constructive, and confidential evaluations while declaring any conflicts of interest that could compromise their impartiality.
If concerns regarding publication ethics arise before or after publication, the journal will investigate them promptly, fairly, and confidentially. When necessary, appropriate editorial measures—including corrections, expressions of concern, or article retractions—will be implemented to maintain the integrity of the published literature.
Annals of Leukemia Research is dedicated to fostering ethical scientific publishing and supporting high-quality research that advances the understanding, diagnosis, treatment, and prevention of leukemia and other hematologic disorders, ultimately contributing to improved patient care and scientific progress.
